Malaysia Chronic Cough Therapeutics Market Analysis

Malaysia Chronic Cough Therapeutics Market Executive Summary

Malaysia Chronic Cough Therapeutics Market was valued at $10 Mn in 2022 and is estimated to reach $19 Mn in 2030, exhibiting a CAGR of 8.3% during the forecast period.

A chronic cough is characterized by its persistence for more than eight weeks, setting it apart from short-term coughs associated with temporary conditions. In contrast to transient coughs typically linked to infections, a chronic cough may indicate a prolonged underlying health issue. Conditions such as asthma, chronic obstructive pulmonary disease (COPD), gastroesophageal reflux disease (GERD), postnasal drip, and certain medications are common culprits behind chronic cough. It is crucial to identify and address the underlying cause through a comprehensive medical evaluation for effective management. Chronic cough can significantly impact the quality of life, often necessitating a holistic, multidisciplinary approach that involves healthcare professionals like pulmonologists, gastroenterologists, or ear, nose, and throat (ENT) specialists.

In Malaysia, the prevalence of chronic cough among 117 patients aged 18 and above reveals that the highest occurrence is within the above 60 age group, accounting for 35.9%. In this population, post-infectious cough accounts for 35.9% of chronic cough cases, with angiotensin-converting enzyme inhibitor-related cough following at 12%. Significant morbidities, such as herniation, rib fracture, arrhythmias, syncope, and stroke, are linked to a persistent cough. Notably, one of the most common causes of referrals to chest doctors is a persistent cough with no clear cause. The treatment of uncontrollably persistent cough is a significant obstacle for family doctors. Clinical decisions, often leading to poor outcomes, may be influenced by deviations from established clinical guidelines, lack of physician confidence, and exacerbated by increasing patient dissatisfaction. The complexity of chronic cough highlights the need for a comprehensive medical examination and the application of evidence-based approaches in its treatment.

Novartis achieved a significant milestone when the U.S. Food and Drug Administration (FDA) granted approval for the Levoquin (levofloxacin) inhalation solution. This approval is specifically for the treatment of cystic fibrosis patients grappling with Pseudomonas aeruginosa lung infections. These infections are known to contribute to chronic coughs, making this development a noteworthy advancement in addressing the healthcare needs of individuals facing this challenging condition.

Market Dynamics

Market Growth Drivers

Prevalence of Smoking: The prevalence of smoking in Malaysia continues to be notably elevated, with around 21.3% of Malaysian adults, equivalent to approximately 4.9 Mn individuals, reported as current smokers. This high prevalence underscores smoking as a significant factor contributing to respiratory issues, notably chronic cough. Recognizing the adverse health impacts of smoking-induced cough, there is a growing demand for diverse therapeutic interventions for chronic cough.

High Prevalence of Chronic Cough: The escalation of respiratory issues is linked to the increasing trend of urbanization and changes in lifestyle, such as smoking and exposure to air pollutants. The prevalence of chronic cough and its related complications is on the rise. The elderly population, more vulnerable to persistent health issues, is especially prone to conditions like chronic cough.

Growing Awareness and Diagnosis: The increased awareness and diagnosis of chronic cough are fuelled by improved healthcare infrastructure and rising disposable incomes, allowing for more effective identification and treatment options. Government and NGO campaigns play a vital role in disseminating information about cough symptoms and encouraging timely diagnosis. Additionally, the accessibility of medical advice through online platforms facilitates easier and quicker consultations, contributing to prompt diagnosis and treatment. This convergence of enhanced infrastructure, awareness initiatives, and online accessibility signifies a positive trend in addressing and managing chronic cough, ultimately expanding the market for chronic cough therapeutics.

Market Restraints

High Treatment Cost: The elevated costs associated with imported and branded cough medications pose a financial challenge for a considerable segment of the population, rendering effective treatment financially out of reach for many. The affordability barrier extends to seeking consultation with pulmonologists or other specialists for the diagnosis and management of chronic cough, compounding the issue by making access to proper care an expensive endeavor. This financial strain creates a significant obstacle to the chronic cough therapeutics market expansion.

Cultural Perceptions and Traditional Remedies: Individuals in Malaysia may rely on homeopathic or traditional remedies as a result of cultural attitudes and preferences that may affect how persistent coughs are perceived. Persuading medical professionals and patients to adopt contemporary treatment alternatives could pose a constraint on the industry.

Regulatory and Reimbursement Hurdles: The integration of novel and advanced treatment options may face impediments due to prolonged processes of drug approval and rigorous registration prerequisites. The stringent nature of these requirements can potentially delay the introduction of innovative therapies into the healthcare landscape. Additionally, the financial accessibility of such advancements is further constrained by limitations in insurance coverage, both from the public and private sectors. The incomplete coverage of substantial costs associated with these medications places a significant financial burden on patients, impacting their ability to access and afford potentially life-changing treatments.

Healthcare Policies and Regulatory Landscape

The primary regulatory body responsible for overseeing pharmaceutical treatments in Malaysia is the National Pharmaceutical Regulating Agency (NPRA), which operates under the Ministry of Health. NPRA plays a crucial role in ensuring the quality, safety, and efficacy of pharmaceutical products by managing various processes such as medication registration, approval, and post-market surveillance. Upholding strict adherence to Good Manufacturing Practice (GMP) guidelines is essential to guarantee consistent pharmaceutical quality throughout the production process. The Pharmacy Practice and Poisons Act of 1952 governs the sale and distribution of therapeutic drugs, as well as other pharmacy-related activities in Malaysia. Continuous post-market surveillance is conducted to evaluate the ongoing safety and efficacy of approved medicines. Essential medications that meet specific standards are listed on the National Essential Medicines List. Furthermore, Malaysia is exploring the application of Health Technology Assessment to assess the impact of emerging health technologies, including medications.

Competitive Landscape

Key Players

• Pfizer
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• AstraZeneca
• Boehringer Ingelheim
• Teva Pharmaceuticals
• Hikma Pharmaceuticals
• Abbott Laboratories